RxDoctor Payments Data

Bhuvana Sunil

Tacoma, WANPI 1457756926

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $723 of the $1,023 with a category attached, or 70.7%. 11 manufacturers reported payments, led by Novo Nordisk at 39.4% of the total.

$1,023in general payments, 2019–2025

Across 53 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$403
  • Sanofi-aventis U.S. LLC$250
  • Amphastar Pharmaceuticals, Inc.$102
  • Medtronic$53
  • Abbott$50
  • Sequel Med Tech, LLC$45
  • plus $120 from 5 others
$553,180in research payments, 2019–2025

Across 640 payments — averaging $864.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$177K
  • Medtronic$114K
  • Sanofi US Services Inc.$80K
  • Rhythm Pharmaceuticals, Inc.$76K
  • AbbVie$53K
  • Antares Pharma, Inc.$31K
  • plus $22K from 2 others

What the payments were for

  • Speaking & faculty fees$25024%
  • Food & beverage$72371%
  • Other$505%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Where these figures come from

Is this you, or does something look wrong? →